Suchergebnisse - "Bouattour, M."

ASO Author Reflections: Real-World Outcomes of Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab for Surgical Conversion of Borderline Resectable Cholangiocarcinoma.

Autoren: Dong Y Starlinger P

Quelle: Annals of surgical oncology [Ann Surg Oncol] 2025 Oct; Vol. 32 (10), pp. 7268-7269. Date of Electronic Publication: 2025 Aug 20.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: In Process; MEDLINE

ASO Author Reflections: Long-Term Outcomes According to Surgical Margin in Mass-forming Cholangiocarcinoma-The Role of R1vasc.

Autoren: Torzilli G Milana F Procopio F

Quelle: Annals of surgical oncology [Ann Surg Oncol] 2025 Jun; Vol. 32 (6), pp. 4429-4430. Date of Electronic Publication: 2025 Mar 22.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: In Process; MEDLINE

Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.

Autoren: Persano, Mara Casadei-Gardini, Andrea Tada, Toshifumi et al.

Quelle: Oncology; 2025, Vol. 103 Issue 6, p456-468, 13p

Schlagwörter: ANTINEOPLASTIC agents, BEVACIZUMAB, SORAFENIB, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, MULTIVARIATE analysis, LONGITUDINAL method, MEDICAL records, ACQUISITION of data, HEPATOCELLULAR carcinoma, OVERALL survival, PROPORTIONAL hazards models

Predicting tumor micronecrosis in hepatocellular carcinoma using pretreatment contrast-enhanced CT radiomics model: a multi-center study.

Autoren: Wang, Yangyang Huang, Chao Tian, Yu et al.

Quelle: NPJ Precision Oncology; 11/14/2025, Vol. 9 Issue 1, p1-10, 10p

UK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme.

Autoren: Daniels, Harry Hassan, Mona Babiker, Omer et al.

Quelle: Cancers; Sep2025, Vol. 17 Issue 17, p2732, 10p

Schlagwörter: THERAPEUTIC use of monoclonal antibodies, BILE duct tumors, COMBINATION drug therapy, CISPLATIN, PATIENT safety, IMMUNOTHERAPY, COMPUTED tomography, FISHER exact test, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, MONOCLONAL antibodies, KAPLAN-Meier estimator, LOG-rank test, LIVER diseases, GALLBLADDER diseases, GEMCITABINE, DRUG efficacy, MEDICAL records, ACQUISITION of data, RESEARCH, STATISTICS, ALANINE aminotransferase, PROGRESSION-free survival, DATA analysis software, COMPARATIVE studies, SURVIVAL analysis (Biometry), CONFIDENCE intervals, OVERALL survival

Geografische Kategorien: UNITED Kingdom

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study.

Autoren: Kim, Yoon Jun Merle, Philippe Finn, Richard S. et al.

Quelle: Liver Cancer (2235-1795); 2025, Vol. 14 Issue 4, p391-407, 17p

Schlagwörter: REGORAFENIB, HEPATOCELLULAR carcinoma, PRAGMATISM, TREATMENT effectiveness, SAFETY, SCIENTIFIC observation, ADVERSE health care events, OVERALL survival

Effective control in MSI-high unresectable intrahepatic cholangiocarcinoma treated with gemcitabine/cisplatin/durvalumab and proton beam therapy: a case report.

Autoren: Nosaka, Takuto Naito, Hironori Murata, Yosuke et al.

Quelle: Frontiers in Immunology; 2025, p1-6, 6p

Schlagwörter: CHOLANGIOCARCINOMA, GEMCITABINE, TREATMENT effectiveness, MICROSATELLITE repeats, MEDICAL research, CISPLATIN, IMMUNE checkpoint inhibitors, PROTON therapy

Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG).

Autoren: Majidova, Nargiz Yaslıkaya, Sendag Mıldanoglu, Maral Martin et al.

Quelle: Turkish Journal of Gastroenterology; May2025, Vol. 36 Issue 5, p293-301, 9p

Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.

Autoren: Rossari, Federico Tada, Toshifumi Suda, Goki et al.

Quelle: Liver Cancer (2235-1795); 2024, Vol. 13 Issue 5, p522-536, 15p

Schlagwörter: ASPARTATE aminotransferase, PROGNOSIS, TREATMENT effectiveness, NON-alcoholic fatty liver disease, ETIOLOGY of diseases

Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II Trial.

Autoren: Gros L Bouattour M Dumont C et al.

Quelle: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2025 Aug; Vol. 45 (8), pp. e70196.

Publikationsart: Journal Article; Clinical Trial, Phase II; Multicenter Study

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101160857 Publication Model: Print Cited Medium: Internet ISSN: 1478-3231 (Electronic) Linking ISSN: 14783223 NLM ISO Abbreviation: Liver Int Subsets: MEDLINE

MeSH-Schlagworte: Sunitinib*/therapeutic use , Sunitinib*/adverse effects , Sunitinib*/blood , Cholangiocarcinoma*/drug therapy , Cholangiocarcinoma*/mortality , Cholangiocarcinoma*/pathology , Bile Duct Neoplasms*/drug therapy , Bile Duct Neoplasms*/mortality , Bile Duct Neoplasms*/pathology , Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/adverse effects , Antineoplastic Agents*/therapeutic use , Antineoplastic Agents*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; France ; Progression-Free Survival ; Adult ; Vascular Endothelial Growth Factor A/blood ; Aged, 80 and over

Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.

Autoren: Ren, Zhenggang Shao, Guoliang Shen, Jie et al.

Quelle: Cancer Immunology, Immunotherapy; Feb2025, Vol. 74 Issue 2, p1-12, 12p

Schlagwörter: OVERALL survival, HEPATOCELLULAR carcinoma, PROGRESSION-free survival, REVIEW committees, BEVACIZUMAB

Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1- mutant cholangiocarcinoma.

Autoren: Zabransky, Daniel J. Kartalia, Emma Lee, Jae W. et al.

Quelle: Hepatology (02709139); Sep2025, Vol. 82 Issue 3, p599-611, 13p

Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients.

Autoren: Zhai, Yirui Zhang, Yefan Wu, Fan et al.

Quelle: Frontiers in Immunology; 2025, p1-11, 11p

Schlagwörter: HEPATOCELLULAR carcinoma, IMMUNE checkpoint inhibitors, RADIOTHERAPY, METASTASIS, FIELD research, ADVERSE health care events, TREATMENT effectiveness

Report from the 26th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Hepatocellular and Biliary Tract Cancer, Saskatoon, Saskatchewan, 17–18 October 2024.

Autoren: Ravi, Deepti Ahmed, Shahid Anderson, Blaire et al.

Quelle: Current Oncology; Jul2025, Vol. 32 Issue 7, p398, 18p

Schlagwörter: HEPATOCELLULAR carcinoma, BILIARY tract cancer, IMMUNOTHERAPY, MOLECULAR diagnosis, CANCER treatment, INTEGRATED health care delivery, TREATMENT effectiveness, CONFERENCES & conventions

Geografische Kategorien: WESTERN Canada

Clinical outcomes of combination therapy for hepatocellular carcinoma in a predominantly hispanic South Texas population.

Autoren: Hoverson, John Qi, Jonathan Mehmken, Cameron et al.

Quelle: Frontiers in Oncology; 2025, p1-10, 10p

The real-world clinical effectiveness of durvalumab in advanced biliary tract cancer: a mimic comparative analysis through survival data reconstruction.

Autoren: Ji, Hong-xiang Si, Ma-Hui Sun, Zhe et al.

Quelle: Frontiers in Immunology; 2025, p1-12, 12p

Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Post-Surgery: A Scoping Review.

Autoren: Zhang, Wei-Zheng Chin, Kok-Yong Zakaria, Roshaya et al.

Quelle: International Journal of Medical Sciences; 2025, Vol. 22 Issue 14, p3709-3721, 13p

Effects of Ozone Therapy on Adverse Events and Inflammatory Markers in Patients With Hepatocellular Carcinoma Undergoing Interventional Therapy.

Autoren: Zhu, Minghui Ran, Yujie Huang, Yufei et al.

Quelle: Gastroenterology Research & Practice; 11/12/2025, Vol. 2025, p1-9, 9p

Schlagwörter: PREVENTION of drug side effects, INFLAMMATION treatment, PEARSON correlation (Statistics), RISK assessment, HEPATIC artery, T-test (Statistics), ALPHA fetoproteins, CHEMOEMBOLIZATION, FISHER exact test, LOGISTIC regression analysis, ASPARTATE aminotransferase, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, CHI-squared test, MANN Whitney U Test, CANCER patients, CANCER chemotherapy, LONGITUDINAL method, ODDS ratio, COMBINED modality therapy, MEDICAL records, ACQUISITION of data, ALANINE aminotransferase, INFLAMMATION, INTRA-arterial infusions, CONFIDENCE intervals, DATA analysis software, ADVERSE health care events, HEPATOCELLULAR carcinoma, OZONE therapy, BIOMARKERS, DISEASE risk factors

Geografische Kategorien: CHINA

Prediction of Microsatellite Instability in Colorectal Cancer Using Two Internally Validated Radiomic Models.

Autoren: Galluzzo, Antonio Danti, Ginevra Calistri, Linda et al.

Quelle: Tomography: A Journal for Imaging Research; Nov2025, Vol. 11 Issue 11, p126, 18p

Preliminary experience of lenvatinib, tislelizumab and transcatheter arterial chemoembolization for BCLC stage C hepatocellular carcinoma: a phase II study.

Autoren: Nong, Xiang Yao, Yu Xie, Jinlong et al.

Quelle: BMC Cancer; 10/22/2025, Vol. 25 Issue 1, p1-12, 12p

Schlagwörter: HEPATOCELLULAR carcinoma, LIVER cancer, TREATMENT effectiveness, IMMUNE checkpoint inhibitors, ANTINEOPLASTIC agents, CHEMOEMBOLIZATION, SAFETY, CLINICAL trials